Docetaxel (Taxotere®)

Common name: Docetaxel
Brand name: Taxotere®
 

What is Docetaxel?

Docetaxel is a chemotherapy drug used in combination with a corticosteroid (such as prednisone or prednisolone) to treat androgen-independent metastatic prostate cancer.


How is Docetaxel administered?

Docetaxel is administered by injection.

What are possible side effects of this treatment?

Everyone responds differently to chemotherapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received docetaxel. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Anemia
  • Bruising / bleeding
  • Changes to taste
  • Diarrhea
  • Fatigue
  • Fluid retention
  • Hair loss
  • Infection
  • Increase in production of tears
  • Loss of appetite
  • Mouth sores
  • Nausea / vomiting
  • Numbness, burning, tingling in hands and feet
  • Pain in joints
  • Rash

Is Docetaxel covered in my province or territory?

Docetaxel is covered by provincial drug programs in:
 
•    Alberta
•    British Columbia
•    Nova Scotia
•    Ontario
•    Quebec
•    Saskatchewan
•    Yukon
 
Docetaxel is not covered by provincial drug programs in:
 
•    New Brunswick
•    Newfoundland & Labrador
•    Prince Edward Island
•    Nunavut
•    Northwest Territories

Unknown if docetaxel is covered by provincial drug programs in:
•    Manitoba



 
    Last Reviewed: July 2017

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More

Prostate Cancer Canada launches first national program in radioligand therapy

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation.
More


Click here for news archive